Business Context and Reporting Period
Company: BioCryst Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: BioCryst is a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule drugs. Key programs include peramivir (an influenza neuraminidase inhibitor) and forodesine (a PNP inhibitor for oncology and autoimmune diseases). The company relies heavily on collaborative agreements and government contracts, specifically a $102.6 million contract with the U.S. Department of Health and Human Services (HHS) for peramivir development.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2009 |
Three Months Ended June 30, 2008 |
Six Months Ended June 30, 2009 |
Six Months Ended June 30, 2008 |
|---|---|---|---|---|
| Revenues | $4,787 | $2,659 | $9,146 | $13,427 |
| Net Loss | $(8,684) | $(12,709) | $(17,976) | $(25,807) |
| Net Loss Per Share (Basic/Diluted) | $(0.23) | $(0.33) | $(0.47) | $(0.68) |
| Research & Development Expenses | $11,213 | $13,373 | $22,502 | $35,271 |
| General & Administrative Expenses | $2,313 | $2,666 | $4,770 | $5,552 |
| Cash and Cash Equivalents (Balance Sheet) | $13,810 (as of June 30, 2009) | |||
| Marketable Securities (Balance Sheet) | $28,446 (as of June 30, 2009) | |||
| Total Current Assets | $57,451 (as of June 30, 2009) | |||
| Total Current Liabilities | $13,464 (as of June 30, 2009) |
Liquidity: As of June 30, 2009, the company held approximately $42.3 million in cash, cash equivalents, and investments. The company reported a decrease in cash of $8.5 million for the six-month period, primarily due to operating losses and a $5.0 million payment to HHS to purchase excess peramivir API.
Material Changes vs. Prior Period
- Revenue: For the three months ended June 30, 2009, revenue increased 80% to $4.8 million from $2.7 million in the prior year quarter. This increase was driven by higher reimbursements from the HHS contract, partially offset by a $4.9 million reserve recorded against revenue in 2008. For the six-month period, revenue decreased 32% to $9.1 million from $13.4 million, driven by reduced HHS and Mundipharma revenues.
- Expenses: R&D expenses decreased significantly for both the quarter (16% decrease) and the six-month period (36% decrease) compared to the prior year. This was due to reduced clinical development costs for peramivir, lower manufacturing costs for forodesine, and lower pre-clinical costs. G&A expenses also declined due to reduced consulting fees.
- Net Loss: The net loss narrowed significantly. For the quarter, the loss decreased to $8.7 million from $12.7 million. For the six months, the loss decreased to $18.0 million from $25.8 million.
- Interest Income: Interest income dropped sharply (from $0.7 million to $0.1 million for the quarter) due to lower average cash balances and significantly lower yields on interest-bearing assets.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Cash Burn Guidance: Management expects net cash use in 2009 to be between $30.0 million and $38.0 million, excluding the one-time $5.0 million API payment. This guidance is subject to clinical milestone achievements.
- Liquidity Sufficiency: The company believes current resources, combined with expected payments from HHS and collaborators, are sufficient to fund operations for at least the next twelve months.
- Peramivir Development:
- i.m. Peramivir: Phase 2 results were not statistically significant; the company is not planning further development of the intramuscular formulation.
- i.v. Peramivir: Focus has shifted to the intravenous formulation. Shionogi (partner in Japan) reported positive Phase 3 results. The company is finalizing plans for U.S. Phase 3 studies.
- Stockpile: The company is preparing inventory for the CDC Strategic National Stockpile and pursuing Emergency Use Authorization (EUA).
- Forodesine: A pivotal Phase 2 trial for cutaneous T-cell lymphoma (CTCL) is ongoing with over 100 patients enrolled. A Phase 2 trial for chronic lymphocytic leukemia (CLL) is also ongoing.
Risks and Contingencies
- HHS Contract Risk: A significant portion of revenue and cash flow depends on the HHS contract. Risks include termination for convenience, cost disallowances, or delays in reimbursement. A $4.9 million reserve was previously recorded for uncertain HHS recoveries related to terminated Phase 3 i.m. studies.
- Dispute with Mundipharma: The company is in a dispute with partner Mundipharma regarding contractual obligations for forodesine development costs. The maximum potential exposure is estimated at $2.5 million; no accrual has been made as of June 30, 2009.
- Capital Requirements: The company expects to incur substantial losses for the foreseeable future and will likely need to raise additional capital to complete development and commercialization. Failure to secure funding could force delays or elimination of programs.
- Regulatory and Clinical Risks: Clinical trials may fail to demonstrate safety or efficacy. Regulatory approval is not guaranteed. The company faces intense competition and relies on third-party manufacturers.
Key Facts for Investor Verification
- HHS Reimbursement Status: Verify the status of discussions with HHS regarding the $4.9 million reserve and the likelihood of future funding beyond the current $102.6 million contract cap.
- Mundipharma Dispute Resolution: Monitor the outcome of the dispute regarding the $2.5 million potential exposure related to forodesine development costs.
- Peramivir Phase 3 Timeline: Confirm the timeline and design of the upcoming U.S. Phase 3 studies for i.v. peramivir and the progress of the EUA review.
- Cash Runway: Assess the company's ability to meet the projected $30-$38 million cash burn for 2009 without dilutive equity raises, given the current cash balance of ~$42.3 million.
- Forodesine Trial Data: Await preliminary data from the pivotal CTCL trial (expected first half of 2010) and updates on the CLL trial (expected end of 2009).